Cardiovascular Benefit of Lowering Low-Density Lipoprotein Cholesterol Below 40 mg/dL
- 27 August 2021
- journal article
- letter
- Published by Wolters Kluwer Health in Circulation
- Vol. 144 (21) , 1732-1734
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular riskAtherosclerosis, 2019
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskEuropean Heart Journal, 2019
- 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive SummaryJACC, 2019
- Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a StatinJAMA Cardiology, 2017
- Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trialThe Lancet, 2017
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseNew England Journal of Medicine, 2017